Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling.
Targeting the IL-13 pathway appears to be a viable approach to ameliorate pulmonary inflammation and remodeling. Support for this hypothesis comes from preclinical and preliminary clinical data. Diverse approaches have been used to target the IL-13 pathway, including neutralizing antibodies specific for IL-13, targeting IL-13 receptors using antibodies or chimeric proteins, and therapeutics that target the downstream signaling molecules that are activated upon binding of the IL-13 receptor to its ligand. This review summarizes the progress made in the development of therapeutics targeting the IL-13 pathway for treating diseases associated with inflammation and remodeling of the lung.
Blease
Kate
K
Celgene Corp, San Diego, CA 92121, USA. kblease@celgene.com
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D016535:Bronchial Hyperreactivity / Q000188:drug therapy*; D006801:Humans; D018793:Interleukin-13 / Q000037:antagonists & inhibitors*; D015847:Interleukin-4 / Q000037:antagonists & inhibitors; D011658:Pulmonary Fibrosis / Q000188:drug therapy*; D053660:Receptors, Interleukin-13 / Q000037:antagonists & inhibitors; D050800:STAT6 Transcription Factor / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D018793:Interleukin-13; D053660:Receptors, Interleukin-13; D050800:STAT6 Transcription Factor; D015847:Interleukin-4